Literature DB >> 8467818

Protein analyses in cerebrospinal fluid. I. Influence of concentration gradients for proteins on cerebrospinal fluid/serum albumin ratio.

K Blennow1, P Fredman, A Wallin, C G Gottfries, G Långström, L Svennerholm.   

Abstract

Concentration gradients in lumbar cerebrospinal fluid (CSF) for albumin and IgG were studied in 8 healthy individuals and 44 neuropsychiatric patients by serial sampling of 6 successive portions of CSF, each containing 4 ml, in all 24 ml. Significant and identical decreases between the first (0-4th ml) and the last (21st-24th ml) portions were found for CSF-albumin (21% decrease, p < 0.0001) and CSF-IgG (21% decrease, p < 0.0001). Therefore, the CSF/serum albumin ratio also showed a significant gradient with a 21% decrease (p < 0.0001), while no gradients were found to the IgG index. These results imply that analyses of proteins in the CSF should be performed on a standardized volume of CSF, preferably the first 12 ml, to allow comparisons of scientific results between various patient groups and controls and between different laboratories and to increase the validity of protein analyses in clinical practice.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8467818     DOI: 10.1159/000116918

Source DB:  PubMed          Journal:  Eur Neurol        ISSN: 0014-3022            Impact factor:   1.710


  14 in total

1.  Both total and phosphorylated tau are increased in Alzheimer's disease.

Authors:  M Sjögren; P Davidsson; M Tullberg; L Minthon; A Wallin; C Wikkelso; A K Granérus; H Vanderstichele; E Vanmechelen; K Blennow
Journal:  J Neurol Neurosurg Psychiatry       Date:  2001-05       Impact factor: 10.154

2.  Measurement of apolipoprotein E (apoE) in cerebrospinal fluid.

Authors:  C Hesse; H Larsson; P Fredman; L Minthon; N Andreasen; P Davidsson; K Blennow
Journal:  Neurochem Res       Date:  2000-04       Impact factor: 3.996

Review 3.  Cerebrospinal fluid biomarker candidates of schizophrenia: where do we stand?

Authors:  Nenad Vasic; Bernhard J Connemann; Robert C Wolf; Hayrettin Tumani; Johannes Brettschneider
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2011-12-16       Impact factor: 5.270

Review 4.  Proteomics of human neurodegenerative diseases.

Authors:  Jing Zhang; C Dirk Keene; Catherine Pan; Kathleen S Montine; Thomas J Montine
Journal:  J Neuropathol Exp Neurol       Date:  2008-10       Impact factor: 3.685

5.  Receptor-mediated transfer of IgG and albumin at cerebrospinal fluid interfaces.

Authors:  Sepp Seyfert; Felicitas Ehlen; Fabian Klostermann
Journal:  J Neural Transm (Vienna)       Date:  2015-01-03       Impact factor: 3.575

6.  Blood-Brain Barrier Disruption Is Initiated During Primary HIV Infection and Not Rapidly Altered by Antiretroviral Therapy.

Authors:  Elham Rahimy; Fang-Yong Li; Lars Hagberg; Dietmar Fuchs; Kevin Robertson; Dieter J Meyerhoff; Henrik Zetterberg; Richard W Price; Magnus Gisslén; Serena Spudich
Journal:  J Infect Dis       Date:  2017-04-01       Impact factor: 5.226

7.  Cerebrospinal fluid beta-amyloid 1-42 concentration may predict cognitive decline in older women.

Authors:  Deborah R Gustafson; Ingmar Skoog; Lars Rosengren; Henrik Zetterberg; Kaj Blennow
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-11-10       Impact factor: 10.154

8.  Confounding factors influencing amyloid Beta concentration in cerebrospinal fluid.

Authors:  Maria Bjerke; Erik Portelius; Lennart Minthon; Anders Wallin; Henrik Anckarsäter; Rolf Anckarsäter; Niels Andreasen; Henrik Zetterberg; Ulf Andreasson; Kaj Blennow
Journal:  Int J Alzheimers Dis       Date:  2010-07-15

Review 9.  A consensus in Korea regarding a protocol to reduce preanalytical sources of variability in the measurement of the cerebrospinal fluid biomarkers of Alzheimer's disease.

Authors:  Sun Ah Park; Ju Hee Kang; Eun Suk Kang; Chang Seok Ki; Jee Hoon Roh; Young Chul Youn; Seong Yoon Kim; Sang Yun Kim
Journal:  J Clin Neurol       Date:  2015-04       Impact factor: 3.077

10.  Location matters: highly divergent protein levels in samples from different CNS compartments in a clinical trial of rituximab for progressive MS.

Authors:  Joakim Bergman; Anders Svenningsson; Per Liv; Tommy Bergenheim; Joachim Burman
Journal:  Fluids Barriers CNS       Date:  2020-07-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.